Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Drugs Are Us, Inc., dba Hopewell Pharmacy
483
•Drugs Are Us, Inc., dba Hopewell Pharmacy•March 21, 2013

Drugs Are Us, Inc., dba Hopewell Pharmacy – FDA 483, Mar 21, 2013

Record Details

This FDA Form 483 document outlines observations made during an inspection of a drug manufacturing facility. The inspection revealed deficiencies in several key areas related to current Good Manufacturing Practices (cGMP).

Firstly, the aseptic processing areas were found to have a deficient system for monitoring environmental conditions. This indicates a potential risk to product sterility and quality, as the facility may not be adequately tracking or controlling critical environmental parameters necessary for aseptic operations.

Secondly, the clothing worn by personnel engaged in the processing of drug products was deemed inappropriate for the duties they perform. This observation suggests a failure to maintain adequate gowning procedures, which are crucial for preventing contamination of drug products, particularly in controlled or sterile environments.

Lastly, the facility was cited for not testing an adequate number of batches of each drug product to determine an appropriate expiration date. This deficiency impacts the stability and shelf-life determination of the drug products, potentially leading to products being distributed with unverified or inaccurate expiration dates, which could compromise their efficacy and safety over time.

These observations collectively point to issues within the facility's quality system and manufacturing controls, specifically concerning environmental monitoring, personnel hygiene/gowning, and stability testing. Addressing these deficiencies is critical for the facility to ensure compliance with cGMP regulations and to maintain the quality, safety, and efficacy of its drug products.

Company
Drugs Are Us, Inc., dba Hopewell Pharmacy
Inspection date
March 21, 2013
Product type
Drugs
Office
New Jersey District Office
People
  • Karen D'Orazio (Investigator)
  • Nicholas A. Violand (Director, Enterprise Regulatory Compliance)
View Company Profile

ID · ce4dd612-2f2c-447c-aca5-e2e1d36b5fb3

Other documents for Drugs Are Us, Inc., dba Hopewell Pharmacy
  • STATE_REFERRAL_LETTER - 2013-03-18March 18, 2013

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Drugs Are Us, Inc., dba Hopewell Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.